DePauw: A Pictorial History

This book was conceived in discussions of the sesquicentennial planning committee called together by President Richard F. Rosser in the spring of 1985 to begin preparations for the celebration of the 150th anniversary of the founding of Indiana Asbury-DePauw University. An editorial committee was appointed to supervise the writing and publication of a series of departmental and school histories as well as a larger pictorial history of the university as a whole. Both President - later Chancellor - Rosser and his successor, President Robert G. Bottoms, encouraged and supported this project from its inception. DePauw: A Pictorial History owes much to its predecessors: Belle A. Mansfield\u27s DePauw University - a Historical Sketch (1901); Irving F. Brown\u27s Indiana Asbury-DePauw University: A History (1914); William W. Sweet\u27s Indiana Asbury-DePauw University, 1837-1937 (1937); and George B. Manhart\u27s DePauw Through the Years (1962). Besides bringing the story down to the present, this volume attempts to present the history of the institution in a new light by combining an analytical narrative with carefully selected illustrations. Each chapter contains, in addition to the main text, several word and picture vignettes and pictorial layouts highlighting significant episodes, personalities, and other features. Most of the text is the work of the two chief authors, who have been colleagues in the history department at DePauw for more than 30 years. John Baughman prepared the initial draft of the first chapter as well as an administrative history of the institution since 1884. He also wrote nearly all the picture captions and some of the vignettes, and played an active editorial role throughout. Clifton Phillips, who serves as the editor of DePauw\u27s sesquicentennial historical publications, was largely responsible for drafting the remaining text and making the final revisions. Former Professor of English Harold Spicer contributed many of the items on student life in both the main text and the vignettes. Associate Professor of History John Schlotterbeck was a member of the editorial committee from the outset and provided the valuable quantitative analysis found in the appendices. Another member of the editorial committee, University Archivist Wesley Wilson, helped to select the illustrations and prepare them for publication. Finally, DePauw alumnus and novelist John Jakes wrote the lively introduction. The authors wish to thank the many persons whose efforts helped to make this volume possible. Several of them are attached to the university\u27s office of public relations: Gregory Rice, university editor; Dian D. Phillips, director of publications; and Mary Rector, photographer. Janae Berry, a freelance layout artist, also contributed to the book. Members of the staff of the university archives, past and present, who furnished research assistance during the project include Eleanor Cammack, David Horn, Julia D. Young, Sharon Cheslik, Susan Moore, Laura Clymer, Joan Cunningham and the late Virginia Brann. We are also grateful to the spouses and families who patiently endured the strains and stresses of a protracted enterprise. We have tried to avoid most of the usual pitfalls of college histories. This has meant resisting the temptation to recount nostalgically the funny stories told around the fraternity house fireplace, faculty eccentricities, presidents\u27 and deans\u27 follies, and the last-minute football victory over Old Siwash, or to flatter wealthy donors and influential alumni and overpraise recent administrations. We have attempted to be fair and evenhanded, noting both trials and triumphs, praising the strengths of the university where appropriate and admitting occasional weaknesses and misadventures. What finally emerges from these pages, we believe, is a late 20th century interpretation of the history of Indiana Asbury-DePauw University that strives for objectivity while necessarily reflecting to some degree the special perspectives of the authors. It is our hope that this volume will make a useful contribution to DePauw\u27s sesquicentennial celebration by providing its readers with a valid record in words and pictures of the institution\u27s first 150 years. It is dedicated to all those who have had a part as students, members of the faculty and administration, trustees, or benefactors, living and dead, in molding the university during the past century and a half. Clifton J. Phillips & John J. Baughman Greencastle, Indiana June 30, 198

Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab vs trastuzumab to prevent recurrences in high-risk HER2 low-expressing breast cancer patients.

PURPOSE: Preclinical data provide evidence for synergism between HER2-targeted peptide vaccines and trastuzumab. The efficacy of this combination was evaluated in HER2 low-expressing breast cancer patients in the adjuvant setting. EXPERIMENTAL DESIGN: A phase IIb, multicenter, randomized, single-blinded, controlled trial enrolled disease-free patients after standard therapy completion (NCT01570036). Eligible patients were HLA-A2, A3, A24, and/or A26+, and had HER2 immunohistochemistry 1+/2+, FISH nonamplified breast cancer, that was node positive and/or hormone receptor negative (triple negative breast cancer [TNBC]). Patients received trastuzumab for one year and were randomized to placebo (granulocyte-macrophage colony-stimulating factor [GM-CSF], control) or nelipepimut-S (NPS) with GM-CSF. Primary outcome was 24-month disease-free survival (DFS). Secondary outcomes were 36-month DFS, safety, and immunologic response. RESULTS: Overall, 275 patients were randomized; 136 received NPS with GM-CSF and 139 received placebo with GM-CSF. There were no clinicopathologic differences between groups. Concurrent trastuzumab and NPS with GM-CSF was safe with no additional overall or cardiac toxicity compared to control. At median follow up of 25.7 (interquartile range, IQR: 18.4-32.7) months, estimated DFS did not significantly differ between NPS and control (HR 0.62, 95% CI: 0.31-1.25, p=0.18). In a planned exploratory analysis of TNBC patients, DFS was improved for NPS vs control (HR 0.26, 95% CI: 0.08-0.81, p=0.01). CONCLUSION: The combination of NPS with trastuzumab is safe. In HER2 low-expressing breast cancer, no significant difference in DFS was seen in the intention-to-treat analysis; however, significant clinical benefit was seen in TNBC patients. These findings warrant further investigation in a phase III randomized trial

Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.

HER2-targeted therapy has not benefited patients with low levels of HER2 expression; however, combination therapy may be effective. Primary analysis of a phase IIb trial investigating the HER2-derived vaccine nelipepimut-S (NPS) did not benefit the intention-to-treat population, but subset analysis showed a benefit in triple-negative breast cancer (TNBC) patients. The subset analysis of this multicenter, randomized, single-blind, phase IIb trial identified significant improvement in 36-month disease-free survival (DFS) between NPS (n = 55) and placebo (n = 44) in TNBC (HR 0.25, p = 0.01) and those who express HLA-A24 (HR 0.41, p = 0.05). The TNBC cohort demonstrated improved 36-month DFS in those with HER2 1+ expression (HR 0.17, p = 0.01), HLA-A24 positivity (HR 0.08, p \u3c 0.01), or in those who received neoadjuvant chemotherapy (HR 0.21, p \u3c 0.01). NPS vaccination with trastuzumab was associated with improved 36-month DFS among patients with TNBC. The observed benefit to this high-risk subgroup warrants confirmation in a phase III trial